Search Results
Search for other papers by Judith Gebauer in
Google Scholar
PubMed
Search for other papers by Claire E Higham in
Google Scholar
PubMed
Department of Endocrinology, University of Manchester, School of Medical Sciences, Manchester, UK
Search for other papers by Victoria Chatzimavridou-Grigoriadou in
Google Scholar
PubMed
Department of Endocrinology, University of Manchester, School of Medical Sciences, Manchester, UK
Search for other papers by Lisa H Barraclough in
Google Scholar
PubMed
Search for other papers by Rohit Kochhar in
Google Scholar
PubMed
Search for other papers by Lucy Buckley in
Google Scholar
PubMed
Search for other papers by Nooreen Alam in
Google Scholar
PubMed
Search for other papers by Claire E Higham in
Google Scholar
PubMed
Background
Radiotherapy-related insufficiency fractures (RRIFs) represent a common, burdensome consequence of pelvic radiotherapy. Their underlying mechanisms remain unclear, and data on the effect of osteoporosis are contradictory, with limited studies assessing bone mineral density (BMD) by dual-energy x-ray absorptiometry (DXA).
Methods
BMD by DXA (Hologic) scan and fracture risk following pelvic RRIF were retrospectively assessed in 39 patients (median age 68 years) at a tertiary cancer centre. Patient characteristics and treatment history are presented narratively; correlations were explored using univariate regression analyses.
Results
Additional cancer treatments included chemotherapy (n = 31), surgery (n = 20) and brachytherapy (n = 19). Median interval between initiation of radiotherapy and RRIF was 11 (7.5–20.8) and that between RRIF and DXA 3 was (1–6) months. Three patients had normal BMD, 16 had osteopenia and 16 osteoporosis, following World Health Organization classification. Four patients were <40 years at the time of DXA (all Z-scores > –2). Median 10-year risk for hip and major osteoporotic fracture was 3.1% (1.5–5.7) and 11.5% (7.1–13.8), respectively. Only 33.3% of patients had high fracture risk (hip fracture >4% and/or major osteoporotic >20%), and 31% fell above the intervention threshold per National Osteoporosis Guidelines Group (NOGG) guidance (2017). Higher BMD was predicted by lower pelvic radiotherapy dose (only in L3 and L4), concomitant chemotherapy and higher body mass index.
Conclusion
At the time of RRIF, most patients did not have osteoporosis, some had normal BMD and overall had low fracture risk. Whilst low BMD is a probable risk factor, it is unlikely to be the main mechanism underlying RRIFs, and further studies are required to understand the predictive value of BMD.